Hikma 'sixth largest US generics firm' following Roxane buy from Boehringer

Hot on the heels of Teva's acquisition of Allergan's generics business, Hikma Pharmaceuticals has agreed to buy US generics firm Roxane Laboratories from Boehringer Ingelheim in a deal worth around $2.65bn, making Hikma "the sixth largest generics company" by revenue in the US. "The US generics market is currently a very attractive place to be," Hikma's CEO Said Darwazah told Scrip. "If you want to grow fast, there is no other market that can provide you with this kind of opportunity."

Under the agreement, London-listed Hikma will pay $1.18bn in cash and issue 40 million new Hikma shares to Boehringer. This...